CHEMISTRY Review Article Jaya Pandey* and AvidhaKulshreshtha Amity University, India Received: September 16, 2015; Published: November 06, 2015 *Corresponding Author: Jaya Pandey, Amity University, Uttar Pradesh, Lucknow-226028, India. Raloxifene: An Effective Selective Estrogen Receptor Modulator Introduction Abstract In recent past, women at risk of breast cancer have got some hope to get their disease managed efectively with the help of molecules termed as Selective Receptor Modulators (SERMs). Statistically, one in eight women gets diagnosed with breast cancer. Many breast cancers are sensitive to the hormone estrogen. It is established that an anomaly in estrogen level causes the breast cancer. Such cancers have estrogen receptors on the surface of their cells. They are called as ER (estrogen receptor) positive cancer. Medicines that block the efects of estrogens have been shown to reduce the risk of breast cancer in women. There are two medicines namely, tamoxifene and raloxifene, approved by FDA for the treatment of breast cancer. While, tamoxifen is already approved for breast cancer treatment and its risk reduction in women who are at high risk of the disease for long, lately, raloxifene, originally approved for the prevention and treatment of osteoporosis has also got approval for breast cancer risk reduction in postmenopausal women with osteoporosis.. Although there are many medicines available in the market but it is yet to access ideal selective estrogen receptor modulator (SERM) that finds a critical balance with anti-cancer and anti-osteoporotic properties. Keywords: Raloxifene; Tamoxifene; SERM; Breast Cancer; Bone Citation: Jaya Pandey and AvidhaKulshreshtha. “Raloxifene: An Efective Selective Estrogen Receptor Modulator”. EC Chemistry 2.1 (2015): 92-96. Raloxifene, [6-Hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl] {4-[2-(piperidin-1-yl) eth-oxy] phenyl} methanone hydrochlo- ride (Figure 1), is an estrogen agonist/antagonist, commonly referred as a selective estrogen receptor modulator (SERM) [1,2] that has benzothiophene heterocyclic moiety. It is the most extensively investigated SERM that partially mimics the efect of estrogens in bone and cardiovascular system, while functioning as an anti estrogen in endometrial and breast tissue. It has been approved for osteoporosis prevention and reduction in risk of fragility fracture [3-6]. Figure 1: Raloxifene Hydrochloride. Cronicon OPEN ACCESS